Provided by Tiger Trade Technology Pte. Ltd.

PROCEPT BioRobotics

17.16
+0.14000.82%
Post-market: 17.15-0.0100-0.06%19:59 EDT
Volume:1.24M
Turnover:21.41M
Market Cap:982.82M
PE:-8.81
High:17.91
Open:17.19
Low:16.95
Close:17.02
52wk High:38.11
52wk Low:16.67
Shares:57.27M
Float Shares:54.47M
Volume Ratio:0.68
T/O Rate:2.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9478
EPS(LYR):-1.7207
ROE:-30.24%
ROA:-14.75%
PB:2.89
PE(LYR):-9.97

Loading ...

PROCEPT BioRobotics (PRCT) Stock Could Be 14% Undervalued After Growth Outlook Holds

Simply Wall St.
·
Jun 20

PROCEPT BioRobotics Shares Drop After Downgrade From Leerink Partners

MT Newswires Live
·
Jun 12

PROCEPT BioRobotics Cut to Market Perform From Outperform by Leerink Partners

Dow Jones
·
Jun 11

Leerink Partners Downgrades PROCEPT BioRobotics to Market Perform From Outperform, Adjusts PT to $29 From $31

MT Newswires Live
·
Jun 11

Procept Biorobotics Corp : Leerink Partners Cuts to Market Perform From Outperform; Cuts Target Price to $29 From $31

THOMSON REUTERS
·
Jun 11

Procept BioRobotics downgraded to Market Perform from Outperform at Leerink

TIPRANKS
·
Jun 11

Top PROCEPT BioRobotics Executive Makes Notable Stock Move

TIPRANKS
·
Jun 11

PROCEPT BioRobotics Shareholders Back Board, Pay and Auditor

TIPRANKS
·
Jun 11

Procept BioRobotics shareholders elect directors at annual meeting

Reuters
·
Jun 11

PROCEPT BioRobotics (PRCT) Is Up 5.7% After New WATER IV Trials Expand Aquablation Testing Scope

Simply Wall St.
·
Jun 08

PROCEPT BioRobotics (PRCT) Receives a Buy from TD Cowen

TIPRANKS
·
Jun 01

Procept Biorobotics® Advances Prostate Cancer Program With Water Iv Study Enrollment Completion and Expanded Ide Approval

THOMSON REUTERS
·
May 28

PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval

GlobeNewswire
·
May 28

A Look At PROCEPT BioRobotics (PRCT) Valuation After Its Better Than Expected Q1 Earnings And Analyst Updates

Simply Wall St.
·
May 27

PROCEPT BioRobotics (PRCT) Gets a Buy from TD Cowen

TIPRANKS
·
May 14

Should PROCEPT BioRobotics’ Reaffirmed 2026 Outlook Amid Wider Losses Require Action From PRCT Investors?

Simply Wall St.
·
May 11

Procept BioRobotics EVP, CTO Barry Templin files initial beneficial ownership statement

Reuters
·
May 01

Procept BioRobotics to present at Bank of America Health Care Conference

Reuters
·
May 01

PROCEPT BioRobotics Price Target Raised to $35.00/Share From $28.00 by Piper Sandler

Dow Jones
·
May 01

Stock Track | PROCEPT BioRobotics Soars 11.56% in Night Session on Strong Q1 Earnings Beat and Upbeat Guidance

Stock Track
·
Apr 30